Simpson Thacher recently represented Catalent Pharma Solutions, Inc. (“Catalent”) in connection with an amendment of its existing senior secured credit facility in order to provide for the borrowing by Catalent of incremental term loans in an aggregate principal amount of approximately $190.8 million, $100 million of which are denominated in dollars and €72.75 million of which are denominated in euros.

Catalent is the global leader in development solutions and advanced drug-delivery technologies, providing worldwide clinical and commercial supply capabilities for drugs, biologics and consumer health products.

The Simpson Thacher team included Alden Millard, Brian Gluck and Adam Moss (Banking and Credit); Xavier Kowalski (Capital Markets); and Taylor Alexander (Tax).